Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price shot up 2.9% during mid-day trading on Monday . The stock traded as high as $34.70 and last traded at $34.10. 5,594,673 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 13,489,024 shares. The stock had previously closed at $33.14.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on HIMS. Bank of America raised their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday. Piper Sandler raised their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 25th. Truist Financial raised their price target on Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research report on Wednesday, February 26th. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $37.31.
Read Our Latest Stock Report on HIMS
Hims & Hers Health Stock Down 3.0 %
The company has a market capitalization of $7.30 billion, a P/E ratio of 74.67 and a beta of 1.37. The business has a fifty day moving average price of $39.02 and a 200 day moving average price of $28.55.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Insider Activity at Hims & Hers Health
In related news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the sale, the chief executive officer now owns 173,655 shares of the company's stock, valued at approximately $5,900,796.90. The trade was a 42.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,034,506 shares of company stock valued at $36,635,024. 17.71% of the stock is owned by insiders.
Institutional Trading of Hims & Hers Health
Institutional investors and hedge funds have recently bought and sold shares of the business. Crewe Advisors LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares during the period. Finally, Summit Securities Group LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at approximately $38,000. Institutional investors own 63.52% of the company's stock.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
